MWNA
DCPH

Marshall Wace North America’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Marshall Wace North America’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,217
Closed -$138K – 1669
2019
Q4 		$138K Buy
+2,217
New +$105K ﹤0.01% 1027
2019
Q2 		– Sell
-57,714
Closed -$1.34M – 1708
2019
Q1 		$1.34M Buy
57,714
+56,315
+4,025% +$1.47M 0.01% 615
2018
Q4 		$29K Buy
+1,399
New +$34.4K ﹤0.01% 1372
2018
Q2 		– Sell
-20,087
Closed -$403K – 1764
2018
Q1 		$403K Sell
20,087
-22,226
-53% -$563K ﹤0.01% 1199
2017
Q4 		$959K Buy
42,313
+14,976
+55% +$293K 0.01% 998
2017
Q3 		$519K Buy
+27,337
New +$501K ﹤0.01% 1062

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace North America's DCPH Position: Q1 2020 in Review

Marshall Wace North America sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2020, closing a stake of 2,217 shares — an estimated $138K sold.

Marshall Wace North America first reported a position in DCPH in Q3 2017 and held it in 6 quarters. The position peaked at $1.34M in Q1 2019. 148 funds tracked by Wall St. Rank hold DCPH as of Q1 2020.

  • Marshall Wace North America reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 2,217 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $138K.
  • Marshall Wace North America first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 6 quarters.
  • Marshall Wace North America's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.34M in Q1 2019.
  • 148 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.